الولايات المتحدة · منصات وبيانات · The Motley Fool

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

نشره The Motley Fool · الولايات المتحدة منذ 1 س

ملخص مفصل

Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.

اقرأ المقال كاملًا على The Motley Fool سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.fool.com)

يستحق القراءة أيضًا

MarketWatch

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

TheStreet

Marvell’s 3 new directors hint at its biggest Lumentum risk

Morningstar

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

ملخص مفصل

مشاركة

يستحق القراءة أيضًا

Budget airlines are going upscale with first-class seats and faster wifi

Amdocs director Yvette Kanouff acquires $100,800 in ordinary shares

Insider trades: Microsoft, Netflix, Boeing among notable names

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

Marvell’s 3 new directors hint at its biggest Lumentum risk

Market News